Using a guinea pig model of allergic asthma, we investigated the possible role of Larginine limitation in the allergen-induced deficiency of nitric oxide (NO) and airway hyperreactivity (AHR) after the early asthmatic reaction, by examining the effects of various concentrations of the NO synthase (NOS) substrate on the responsiveness to methacholine of isolated perfused tracheae from unchallenged (control) animals and from animals 6 h after ovalbumin challenge.
INTRODUCTION
Allergen-induced early and late asthmatic reactions (Booij-Noord et al., 1971) , infiltration and activation of inflammatory cells in the airways (De Monchy et al., 1985; Djukanovic et al., 1990) and an increase in airway reactivity (AHR) to non-specific stimuli, both after the early and after the late asthmatic reaction (Cockroft et al., 1977; Durham et al., 1988) , are important features of allergic asthma.
Endogenous nitric oxide (NO) plays a central role in the regulation of airway tone as well as in asthmatic airway inflammation (Barnes & Belvisi, 1993; Gaston et al., 1994; Barnes & Liew, 1995) , and may be importantly involved in the development of allergeninduced AHR (De Boer et al.,1996; Schuiling et al., 1998a,b) . Thus, NO has a potent bronchodilator action by inducing relaxation of airway smooth muscle (Grueter et al., 1989; Dupuy et al., 1992) , is an important immunomodulator by promoting the proliferation of Th2 lymphocytes (Barnes and Liew, 1995) , and, at high concentrations, may have deleterious effects in the airways by causing mucosal swelling (Kuo et al., 1992) and epithelial damage (Flak & Goldman, 1996) . NO is synthesized from the semi-essential amino acid L-arginine by the enzyme NO synthase (NOS), of which different isoforms have been identified (Forstermann et al., 1991) . Constitutive NOS isoforms (collectively called cNOS) are mainly expressed in inhibitory nonadrenergic noncholinergic nerves, endothelial cells and airway epithelium (Fisher et al., 1992; Kobzik et al., 1993; Asano et al., 1994) , and are thought to be primarily involved in the regulation of airway and vascular tone by the local production of small amounts of NO in reponse to physiological stimuli (Barnes &Belvisi, 1993 ). An inducible isoform of NOS (iNOS), producing large amounts of NO, is induced by proinflammatory cytokines during airway inflammation, particularly in inflammatory and epithelial cells (Barnes &Belvisi, 1993; Hamid et al., 1993; Asano et al, 1994) , and may be involved in the detrimental effects described above.
Various observations have indicated the involvement of endogenous NO in the regulation of airway tone. Thus, in vitro studies have demonstrated that nonselective NOS inhibitors such as N ω -nitro-L-arginine methyl ester (L-NAME) and N G -monomethyl-L-arginine (L-NMMA) cause enhanced muscarinic agonist-, histamine-and substance P-induced constriction of intact perfused guinea pig tracheal tube preparations (Nijkamp et al., 1993; De Boer et al., 1996; Figini et al., 1997) , while endothelin-1 and bradykinin-induced relaxations were reduced in the presence of these inhibitors (Filep et al., 1993; Figini et al., 1996) . In vivo, inhaled NO reversed histamine and methacholine-induced bronchoconstriction in humans (Kacmarec et al., 1996) , guinea pigs (Dupuy et al., 1992) and dogs (Brown et al., 1994) , while administration of L-NAME or L-NMMA caused enhanced bronchoconstriction in response to allergen (Persson et al., 1993) , histamine (Nijkamp et al., 1993; Schuiling et al., 1998b) and bradykinin (Riccardiolo et al., 1994) in the guinea pig and to bradykinin in mild asthmatics (Riccardiolo et al., 1996) .
Using a guinea pig model of acute allergic asthma, characterized by allergen-induced early and late asthmatic reactions, airway inflammation and AHR after both reactions (Santing et al., 1992 (Santing et al., , 1994 , we have recently established that a deficiency of cNOSderived NO contributes to the increased ex vivo responsiveness of isolated perfused tracheae to methacholine and histamine after the early astmatic reaction, at 6 h after inhalational challenge of the animals with ovalbumin aerosol (De Boer et al., 1996) . Similarly, a deficiency of cNOS-derived NO was also found to contribute to the AHR to histamine in vivo after the early asthmatic reaction (Schuiling et al., 1998b) , while restauration of NO activity by induction of iNOS during the late asthmatic reaction contributed to the partial reversal of the AHR after this reaction (Schuiling et al., 1998a) .
The cause of the allergen-induced deficiency of cNOS-derived NO after the early asthmatic reaction is presently unclear. Very recently, by investigating the effects of the O 2 -scavenger superoxide dismutase in perfused tracheal preparations from ovalbumin-challenged guinea pigs, we demonstrated that this deficiency is not caused by depletion of NO due to its reaction with (inflammation-induced) superoxide anions (De Boer et al., 1998) . In the present study, we examined the possibility of a reduced cNOS-derived NO production due to limitation of substrate, by examining the effects of various concentrations of L-arginine on methacholine-induced constriction of perfused tracheal preparations from unchallenged control guinea pigs as well as from ovalbumin-challenged animals obtained at 6 h after the challenge.
METHODS

Animals
Outbred specified pathogen free guinea pigs (Charles River SAVO, Kiszlegg, Germany), weighing 500 -800g, were used in this study. All animals were actively IgE-sensitized to ovalbumin (OA) at three weeks of age as described by Van Amsterdam et al. (1989) . In short, 0.5 ml of an allergen solution containing 100 µg ml -1 ovalbumin and 100 mg ml
Al(OH) 3 in saline was injected intraperitoneally, while another 0.5 ml was divided over seven intracutaneous injection sites in the proximity of lymphe-nodes in the paws, lumbar regions and the neck. The animals were used experimentally in weeks 4 to 8 after sensitization. The animals were group-housed in individual cages in climated animal quarters and given water and food ad libitum, while a 12-h on/ 12-h off light cycle was maintained.
All protocols described in this study were approved by the University of Groningen Animal Health Committee.
Allergen provocation
Ovalbumin provocations were performed by inhalation of aerosolized solutions. The provocations were performed in a specially designed animal cage, in which the guinea-pigs could move freely (Santing et al., 1992) . The volume of the cage was 9 l, which ensured fast replacement of the air inside the cage with aerosol and vice versa. A DeVilbiss nebulizer (type 646, DeVilbiss, Somerset, PA, USA) driven by an airflow of 8 l/min provided the aerosol required, with an output of 0.33 ml min -1 . Allergen provocations were performed by inhalation of increasing aerosol concentrations of 0.5, 1.0, 3.0, 5.0 and 7.0 mg ml -1 ovalbumin in saline for 3 min, separated by 10-min intervals. Allergen inhalations were discontinued when the first signs of respiratory distress were observed. No anti-histaminic was needed to prevent the development of anaphylactic shock. Previous studies measuring pleural pressure changes in ovalbumin sensitized, permanently instrumented, unrestrained guinea pigs have indicated that the allergen-induced early asthmatic reaction induced by this procedure is maximal within 20 min and lasts for up to 5 h (Santing et al., 1992 (Santing et al., , 1994 .
Tracheal perfusion
Six hours after ovalbumin challenge, the guinea pigs were sacrificed. Non challenged IgEsensitized animals were used as controls. The animals were killed by a sharp blow on the head and exsanguinated. The tracheas were rapidly removed and placed in Krebs-Henseleit (KH) solution (37°C) of the following composition (mM): NaCl 117.50, KCl 5.60, MgSO 4 1.18, CaCl 2 2.50, NaH 2 PO 4 1.28, NaHCO 3 25.00, D-glucose 5.50; gassed with 5% CO 2 and 95% O 2 ; pH 7.4.
The tracheas were prepared free of serosal connective tissue and cut into two halves of approximately 17 mm before mounting in a perfusion setup, as described previously (De Boer et al., 1996) . To this aim, the tracheal preparations were attached at each side to stainless steel perfusion tubes fixed in a Delrin perfusion holder. The holder with the trachea was then placed in a water-jacketed organ bath (37°C) containing 20 ml of gassed KH (the serosal or extraluminal (EL) compartment). The lumen was perfused with recirculating KH from a separate 20 ml bath (mucosal or intraluminal (IL) compartment) at a constant flow rate of 12 ml min -1 . Two axially centred side-hole catheters connected with pressure transducers (TC-XX,Viggo-Spectramed B.V., Bilthoven, The Netherlands) were situated at the distal and proximal ends of the trachealis to measure hydrostatic pressures (P outlet and P inlet , respectively). The signals were fed into a differential amplifier to obtain the difference between the two pressures (∆P = P inlet -P outlet ), which was plotted on a flatbed chart recorder (BD 41, Kipp en Zonen, Delft, The Netherlands). ∆P reflects the resistance of the tracheal segment to perfusion and is a function of the mean diameter of the trachea between the pressure taps (Munakata et al., 1989) . The transmural pressure in the trachea was set at 0 cm H 2 O. At the perfusion flow rate used, a baseline ∆P of 0.1 to 1.0 cm H 2 O was measured, depending of the diameter of the preparation.
After a 45 min equilibration period with three washes with fresh KH (both IL and EL), 1 µM isoprenaline was added to the EL compartment for maximal smooth muscle relaxation to assess basal tone. After three washes during at least 30 min, the trachea was exposed to EL 40 mM KCl in KH to obtain a receptor-independent reference response. Subsequently, the preparation was washed 4 times with KH during 45 minutes until basal tone was reached and a cumulative concentration response curve (CCRC) was made with IL methacholine. When used, L-NAME (100 µM) was applied to the IL reservoir, 45 min prior to agonist-addition. L-arginine (0.3, 1.0 and 5.0 mM) and D-arginine (5.0 mM) were added to the EL reservoir, 30 min prior to agonist addition.
Data analysis
To compensate for differences in baseline ∆P and in ∆P changes in response to contractile stimuli due to variation in resting internal diameter of the preparations used, IL responses of the tracheal tube preparations to methacholine were expressed as a percentage of the response induced by EL administration of 40 mM KCl. The contractile effect of 10 mM methacholine (highest concentration) was defined as E max . Using this E max , the sensitivity to methacholine was evaluated as pEC 50 (-log EC 50 ) value.
The results are expressed as means ± s.e. mean. Statistical analysis was performed using the Student's t-test for unpaired observations. Differences were considered statistically significant at P<0.05. 
Chemicals
RESULTS
In perfused tracheal preparations of unchallenged guinea pigs, the non-selective NOS inhibitor L-NAME (0.1 mM, IL) caused a significant 2.0-fold increase in the E max of IL methacholine (P<0.01), without an effect on the sensitivity (pEC 50 ) to this agonist ( Figure  1 , Table 1 ).
In the ovalbumin-challenged group of animals, the ∆P response to KCl was unchanged compared to the unchallenged control group (not shown). However, a 1.9-fold increase in the E max to IL methacholine was observed (P<0.001), without a change in pEC 50 ( Figure 1 , Table 1 ). This increase was not further enhanced in the presence of L-NAME ( Figure 1 , Table 1 ). In the control preparations, 0.3 mM Larginine (EL) caused a significant decrease of the E max to IL methacholine by approximately 40 % (P<0.01), with no significant effect on the pEC 50 for the agonist (Figure 2 , Table 1 ). Higher concentrations of L-arginine (1.0 and 5.0 mM, EL) did not further decrease the responsiveness to methacholine, although there was a tendency to a gradually reduced sensitivity to the agonist (Figure 2 , Table  1 ). In the presence of the inactive enantiomer D-arginine (5.0 mM, EL) the responsiveness to IL methacholine remained unaltered (Figure 2 , Table 1 ). In tracheae obtained from guinea pigs at 6 h after allergen challenge, 1.0 and 5.0 mM L-arginine (EL) caused a significant, dose-dependent decrease of the E max of IL metha- Table 1 ). In addition, there was a small but significant decrease in the pEC 50 for methacholine in the presence of 1.0 mM L-arginine, which did not change further in the presence of 5.0 mM of the NOS substrate (Table 1 ). In the presence of 5.0 mM L-arginine, the responsiveness of the challenged tracheal preparations to methacholine was very similar to that of the unchallenged control preparations (Figures 2 and 3, Table 1 ). As in the control preparations, D-arginine had no effect on the responsiveness to methacholine in the allergen-challenged preparations (Figure 3 , Table 1 ).
Both in the control preparations and in the preparations of allergen-challenged animals, L-NAME and L-and D-arginine had no effect on basal airway tone (not shown).
DISCUSSION
Using the nonselective NOS inhibitor L-NAME, we confirmed our previous finding (De Boer et al., 1996) that methacholine-induced constriction of guinea pig tracheal tube preparations from unchallenged guinea pigs is functionally antagonized by agonist-induced cNOS-derived NO. In the present study, it was also demonstrated that EL administration of the NO precursor arginine significantly reduced the responsiveness to methacholine in a stereoselective manner in these preparations, indicating that the production of agonistinduced endogenous NO may be enhanced by suppletion of substrate, and that the supply of L-arginine is a rate-limiting factor for cNOS activity in normal airways. This is in line with recent observations that oral administration (Kharitonov et al., 1995) as well as inhalation (Sapienza et al., 1998) of L-arginine cause an increase in exhaled NO in healthy human subjects. Table 1 . Effects of L-NAME and L-and D-arginine on the responsiveness to methacholine of intact perfused tracheae from unchallenged and ovalbumin (OA)-challenged guinea pigs.
Unchallenged
OA-challenged
Vehicle 3.01 ± 0.11 55.5 ± 3.1 3.14 ± 0.07 106.4 ± 3.8 The tracheal responsiveness to methacholine was markedly enhanced at 6 h after allergen challenge. As also found previously (De Boer et al., 1996) , the observed airway hyperreactivity was closely mimicked by the administration of L-NAME to unchallenged control preparations, while, in addition, the hyperreactive preparations were unresponsive to the NOS inhibitor, indicating that a deficiency of agonist-induced NO is a major determinant of the observed hyperreactivity. The enhanced responsiveness to methacholine was completely reversed in the presence of 5 mM L-arginine, which indicates that limitation of substrate may underlie the deficiency of NO and subsequent AHR to methacholine after the early asthmatic reaction.
Different mechanisms could account for a limitation of L-arginine for cNOS activity after allergen challenge. First, recent observations in rat alveolar macrophages have indicated that polycationic proteins such as eosinophil-derived major basic protein, which is released during the allergic asthmatic reaction and involved in the development of AHR (Gleich et al., 1988 ) , may cause inhibition of cellular uptake of L-arginine by specific cationic amino acid transporters (Hirschmann et al., 1998) .
Secondly, the bioavailability of L-arginine could be reduced by enhanced arginase activity in the airways. Arginase, which hydrolyzes L-arginine to L-ornithine and urea, is constitutively expressed in many cells throughout the body, including the lung (Aminlari & Vaseghi, 1992) . Studies in murine bone marrow-derived macrophages have recently indicated that the expression of arginase may be selectively enhanced by T H 2 lymphocytederived cytokines (interleukin-4 and interleukin 10), which are involved in allergic inflammation, thus causing reduced NO production in these cells due to substrate depletion (Corraliza et al., 1995) . Enhanced expression of inducible (type II) arginase by cytokines or lipopolysaccharide has also been observed in other cells, and has been proposed to be an important regulatory mechanism of NOS activity (Wang et al., 1995; Gotoh et al., 1996) . Accordingly, in alveolar macrophages it has recently been shown that inhibition of arginase by N ω -hydroxy-D,L-indospicine, a potent and specific arginase inhibitor (Vadon et al., 1996) , causes a shift of L-arginine utilization to the NOS pathway (Hey et al., 1997) .
Other hypothetical mechanisms that might be involved in L-arginine limitation for NOS activity are a reduced L-citrulline-L-arginine recycling (Chakder & Rattan, 1997) , as well as a reduced affinity of cNOS for the substrate. The latter would be in line with the reduced sensitivity to exogenous L-arginine in the challenged preparations, as indicated by the partial effect of 1.0 mM L-arginine in challenged airways compared to full depression of the methacholine response in control preparations.
The observation that the enhanced methacholine reactivity in the NO-deficient tracheae at 6 h after allergen challenge can be fully reversed by L-arginine suggests that only the activity and not the protein expression of cNOS is reduced after allergen challenge. In addition, in a similar in vitro setting, we recently demonstrated that the deficiency of NO in hyperreactive tracheae is not caused by its possible reaction with superoxide anion in the airways (De Boer et al., 1998) .
Different studies have indicated that the present ex vivo findings are relevant to the development of airway hyperreactivity in vivo. Thus, using the same conscious and unrestrained guinea pig model of asthma, we have recently demonstrated that a deficiency of cNOS-derived NO also contributes to the allergen-induced AHR to histamine in vivo, as observed after the early asthmatic reaction (Schuiling et al., 1998b) . In addition, it was demonstrated that restauration of bronchodilating NO activity by induction of iNOS during the late asthmatic reaction may contribute to the partial reversal of the AHR after this reaction (Schuiling et al., 1998a) . However, in the same study, iNOS-derived NO also proved to have detrimental effects on the airway reactivity by promoting airway inflammation and epithelial damage, indicating its dualistic role in the airways. Very interestingly, evidence for a deficiency of cNOS-derived NO modulating airway reactivity was recently also found in patients with severe asthma treated with corticosteroids, which suppresses the expression of iNOS (Riccardiolo et al., 1997) . Thus, while the airway reactivity to bradykinin (and to methacholine) could be significantly increased by inhalation of L-NMMA in patients with mild asthma (Riccardiolo et al., 1996) , a similarly enhanced AHR to bradykinin present in severe asthmatics was insensitive to the NOS inhibitor, indicating that a deficiency of NO contributed to the enhanced airway responsiveness in these patients.
A deficiency of cNOS-derived NO causing AHR to histamine was recently also demonstrated in guinea pigs with a respiratory parainfluenza type 3 infection (Folkerts et al., 1995) . As in the present study, the enhanced airway reactivity could be reversed by Larginine, indicating that a deficiency of the NOS substrate may similarly be involved in virus-induced AHR. Moreover, in allergic asthmatics who were experimentally infected with rhinovirus-16, the increase in the airway reactivity to histamine was inversely correlated with the NO level in exhaled air, indicating the protective role of endogenous NO in virus-induced AHR (De Gouw et al., 1998) .
Since L-arginine was shown to reverse the allergen-induced AHR after the early asthmatic reaction as well as virus-induced AHR, it could have therapeutic potential in patients with asthma. However, since L-arginine may also amplify the inflammatory effects of iNOS-derived NO present in most patients (Sapienza et al., 1998) , its usefulness remains to be established.
In conclusion, our data demonstrate that a deficiency of endogenous NO contributes to the allergen-induced AHR to methacholine after the early asthmatic reaction, which can be reversed by exogenous L-arginine. This indicates that limitation of substrate may cause a reduced cNOS activity and subsequent AHR after the acute asthmatic response.
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